Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 2/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.36 |
| ▸ | NT5E | P21589 | 3/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23348935 | 1.00 | HINT1 (0.38) | HINT1SLC29A1NT5EADORA2BADORA3 | |
| SCHEMBL20841231 | 0.87 | ADORA3 (0.47) | HINT1ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL20058567 | 0.85 | ADORA3 (0.43) | HINT1SLC29A1NT5EADORA2BADORA3 | |
| SCHEMBL19827691 | 0.85 | HINT1 (0.41) | HINT1SLC29A1NT5EADORA2BADORA3 | |
| SCHEMBL19525778 | 0.83 | HINT1 (0.40) | HINT1NT5EADORA2BADORA3ADORA2A | |
| SCHEMBL23348945 | 0.83 | HINT1 (0.48) | HINT1NT5E | |
| SCHEMBL23010331 | 0.83 | NT5E (0.38) | HINT1SLC29A1NT5EADORA2BADORA3 | |
| SCHEMBL20059085 | 0.83 | HINT1 (0.48) | HINT1NT5E | |
| SCHEMBL25713475 | 0.82 | HINT1 (0.43) | HINT1SLC29A1NT5EADORA2BADORA3 | |
| SCHEMBL20754387 | 0.81 | SLC29A1 (0.33) | HINT1SLC29A1ADORA2BADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160476-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION | JANSSEN BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |